Clinical trials: multiple sclerosis
Multiple Sclerosis, Secondary Progressive
BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis
The primary objective of the study is to investigate whether treatment with BG00012 (dimethyl fumarate) compared with placebo slows the accumulation of disability not related to relapses in participants with secondary progressive…
- Trial name
- INSPIRE (NCT02430532)
- Testing
- dimethyl fumarate
- Where
- 18 sites in United States, Belgium and 4 more
- Volunteers
- 58 people
- Sponsor
- Biogen
Alzheimer Disease, Parkinson Disease
Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions
Ultimately a marker of microglial activation could be used for large-scale quantitative brain imaging trials in Alzheimer Disease (AD), Parkinson Disease (PD) or Multiple Sclerosis (MS), specifically to investigate the agent as…
- Conditions
- Alzheimer Disease, Parkinson Disease, Multiple Sclerosis
- Trial name
- NCT00970333
- Testing
- [18F]-FEPPA
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Institute for Neurodegenerative Disorders
Multiple Sclerosis
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
This study will utilize a prospective, observational, exposure cohort design to examine pregnancy and infant outcomes in women and infants who are exposed to siponimod during pregnancy to treat MS.
- Trial name
- NCT04933552
- Testing
- Siponimod
- Where
- United States
- Volunteers
- 867 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Evaluating Intervention Responsiveness in People With Multiple Sclerosis
The purpose is to see how multiple sclerosis (MS) is associated with strength and sensation using MRI, in persons with MS. The investigators will also see whether exercise can improve these symptoms for persons with MS.
- Trial name
- NCT01632293
- Testing
- progressive resistance training
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Multiple Sclerosis
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod versus interferon β-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.
- Trial name
- TRANSFORMS (NCT00340834)
- Testing
- Fingolimod 1.25 mg, Fingolimod 0.5 mg, Interferon β-1a 30 µg
- Where
- 170 sites in United States, Argentina and 16 more
- Volunteers
- 1,292 people
- Sponsor
- Novartis
Relapsing Remitting Multiple Sclerosis
Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
The purpose of this study is to evaluate the impact of an early treatment with Natalizumab on the management of the progressive nature of Relapsing Remitting Multiple Sclerosis (RRMS).
- Trial name
- TYPIFI (NCT04832399)
- Testing
- Natalizumab
- Where
- 18 sites in Portugal
- Volunteers
- 60 people
- Sponsor
- Biogen
Relapsing Multiple Sclerosis
Study of Evobrutinib in Participants With RMS (evolutionRMS 1)
The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS).
- Trial name
- NCT04338022
- Testing
- Teriflunomide, Evobrutinib
- Where
- 279 sites in United States, Argentina and 29 more
- Volunteers
- 1,124 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
GSK239512 DDI Study
The study will determine the effect of 400 mg once daily of ketoconazole at steady state on the pharmacokinetics of a single oral dose of GSK239512 in young healthy volunteers.
- Trial name
- NCT01802931
- Testing
- GSK239512, ketoconazole
- Where
- Australia
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients
This study aims to evaluate the effect of Metformin as add- on therapy for improving the outcome in RRMS patients.
- Trial name
- NCT05298670
- Testing
- MetFORMIN 1000 Mg Oral Tablet, Interferon beta-1a
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- German University in Cairo
Multiple Sclerosis
Clinical Investigation to Validate the Safety and Performance of the ABLE Exoskeleton Device for Individuals With Multiple Sclerosis in a Clinical Setting
The primary objective of the study is to validate the safety and performance of the ABLE Exoskeleton device in people with multiple sclerosis during a 10-session gait training program in a clinical setting.
- Trial name
- NCT06261541
- Testing
- ABLE Exoskeleton
- Where
- Spain
- Volunteers
- 33 people
- Sponsor
- ABLE Human Motion S.L.
Multiple Sclerosis
Cognitive and Emotion Regulation Training in MS
The investigators propose to conduct a randomized feasibility study of mindfulness meditation training (MMT) relative to an active cognitive training control group and waitlist control group in improving emotional regulation in…
- Trial name
- CERT-MS (NCT02717429)
- Testing
- Mindfulness Meditation, Computerized Cognitive Training
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Ohio State University
Healthy, Neurodegenerative Disease
Brain Health Registry: An Online Registry to Identify and Assess Subjects for Brain Research
The overall goal of this project is to identify, assess and longitudinally monitor subjects who are interested in participating in brain research.
- Trial name
- BHR (NCT02402426)
- Where
- United States
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Multiple Sclerosis, Kinesiophobia
Evaluation of the Presence and Effects of Kinesiophobia in Multiple Sclerosis
The aim of this study was to evaluate the presence of kinesiophobia in multiple sclerosis and to investigate the effect of kinesiophobia on physical activity, functional status, quality of life and depression.
- Trial name
- NCT06167447
- Testing
- questionnaire and examination
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Gazi University
Multiple Sclerosis
Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate
Hypothesis: Treatment with Glatiramer acetate prevents deterioration of gait in multiple sclerosis (MS) patients. During the study patients will undergo a 3 dimensional gait analysis before starting treatment with glatiramer…
- Trial name
- NCT00331747
- Testing
- Glatiramer acetate
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Sheba Medical Center
Multiple Sclerosis, Diabetes
An Observational Post-Marketing Safety Registry of Sativex®
The purpose of this registry is to monitor safety outcomes of patients who are receiving Sativex® for Multiple Sclerosis (MS) spasticity and for off-label indications in the United Kingdom (UK), Germany and Sweden.
- Conditions
- Multiple Sclerosis, Diabetes, Cancer, Neuropathic Pain
- Trial name
- NCT02073474
- Testing
- Sativex®
- Volunteers
- 978 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis, RRMS
Multicenter Prospective Study Analyzing the Occurrence of Multiple Sclerosis Relapses Without Radiological Evidence: Myth or Reality?
The MYTH-MS study is a multicenter prospective study investigating the occurrence of clinical relapses in patients with relapsing-remitting multiple sclerosis (RRMS) in the absence of radiological activity on MRI.
- Conditions
- Multiple Sclerosis, RRMS, Multiple Sclerosis (MS) - Relapsing-remitting
- Trial name
- MYTH-MS (NCT07545889)
- Testing
- Early Cerebro-spinal MRI, Biomarker Assessment, Clinical and Neuropsychological Evaluations
- Where
- 8 sites in France
- Volunteers
- 136 people
- Sponsor
- University Hospital, Strasbourg, France
Multiple Sclerosis
Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS)
The study is designed to determine the effect of weekly intramuscular (IM) administration of 30 mcg Avonex (interferon beta 1a) on safety parameters and gadolinium (Gd) enhanced and T2-weighted cranial magnetic resonance imaging…
- Trial name
- Avonex China (NCT01181115)
- Testing
- Avonex
- Where
- 10 sites in China
- Volunteers
- 60 people
- Sponsor
- Biogen
Multiple Sclerosis
Comparative Effectiveness Study Telerehab Versus Conventional
This study aims to compare the effectiveness of an exercise program delivered in a conventional facility-based format versus a telerehabilitation format, which takes place in the home.
- Trial name
- NCT03468868
- Testing
- Exercise program for people with MS
- Where
- 9 sites in United States
- Volunteers
- 379 people
- Sponsor
- Shepherd Center, Atlanta GA
Multiple Sclerosis
Impact of Adding Cognitive Behaviour Therapy to Supervised Pilates-based Core Stability Training in Patients With Multiple Sclerosis
To investigate the effect of adding cognitive behaviour therapy to supervised Pilates-based core stability training on balance, walking, fatigue and function in patients with multiple sclerosis
- Trial name
- MS (NCT05993819)
- Testing
- pilates based core stability training and congnitive therapy, Pilates based core stability training
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Cairo University
Multiple Sclerosis
Examining the Effects of Video-game Exercise on Mobility and Brain Plasticity in Individuals With Multiple Sclerosis
Dance Dance Revolution (DDR) may offer an innovative and highly effective format for delivering exercise programs to people with multiple sclerosis (MS).
- Trial name
- NCT01780792
- Testing
- Dance Dance Revolution video game play
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ohio State University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.